Development and validation of a yeast high-throughput screen for inhibitors of Aβ42 oligomerization
SUMMARY Recent reports point to small soluble oligomers, rather than insoluble fibrils, of amyloid β (Aβ), as the primary toxic species in Alzheimer’s disease. Previously, we developed a low-throughput assay in yeast that is capable of detecting small Aβ42 oligomer formation. Specifically, Aβ42 fuse...
Main Authors: | Sei-Kyoung Park, Scott D. Pegan, Andrew D. Mesecar, Lisa M. Jungbauer, Mary Jo LaDu, Susan W. Liebman |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2011-11-01
|
Series: | Disease Models & Mechanisms |
Online Access: | http://dmm.biologists.org/content/4/6/822 |
Similar Items
-
Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs
by: Sei-Kyoung Park, et al.
Published: (2016-01-01) -
Modulation of Aβ<sub>42 </sub>low-n oligomerization using a novel yeast reporter system
by: Liebman Susan, et al.
Published: (2006-09-01) -
Endocytic pathways mediating oligomeric Aβ42 neurotoxicity
by: Laxton Kevin, et al.
Published: (2010-05-01) -
Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation
by: Jill A. White, et al.
Published: (2005-04-01) -
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1–42
by: Barbara L. Trommer, et al.
Published: (2005-02-01)